Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
Abstract
Overview
Introduction: The structured Benefit–risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment
assessments. We applied BRAT to compare the benefit–risk profile of ranibizumab 0.5 mg versus laser photocoagulation for the
treatment of diabetic macular oedema (DMO). Methods: One-year data for the ranibizumab 0.5 mg pro re nata (PRN) and laser
arms of the phase III trials RESPOND (NCT01135914; n=220), RESTORE (NCT00687804; n=345), and REVEAL (NCT00989989; n=396)
were included in the analysis. The benefit measures included ≥10 letters gain/avoidance of loss in best-corrected visual acuity (BCVA),
achieving central retinal thickness (CRT) <275 μm, and 25-item Visual Function Questionnaire (VFQ-25) outcomes. The risks measures
included endophthalmitis, intraocular pressure increase, hypertension, proteinuria, arterial/venous thromboembolic events and deaths.
Results: Ranibizumab treatment provided significant benefits compared with laser for ≥10 letter BCVA gain at month 12 (387/1,000 versus
152/1,000 patients), CRT <275 μm at 12 months (474/1,000 versus 348/1,000 patients), and improvement of ≥6.06 on the VFQ-25 near
activities subscale (325/1,000 versus 245/1,000 patients). Results for the risk measures were similar for both treatments. Conclusions:
Superior clinically relevant outcomes were observed with ranibizumab 0.5 mg PRN compared with laser without compromising on safety.
This analysis further supports the positive benefit–risk profile of ranibizumab 0.5 mg PRN.
Keywords
Ranibizumab, laser, diabetic macular oedema, benefit–risk profile
Article Information
Disclosure
Focke Ziemssen is consultant for Alimera, Allergan, Bayer
Healthcare, Boehringer Ingelheim, Biogen, Novartis and Roche. Cornelia
Dunger-Baldauf, Philippe Margaron and Howard Snow are employees of
Novartis Pharma AG., Basel, Switzerland. William David Strain reports
grants and personal fees from Novartis, during the conduct of the study,
personal fees from Boehringer Ingelheim, Eli-Lilly, Janssen, Pfizer and
Novo-Nordisk outside the submitted work. Alan Cruess has nothing to
declare in relation to this article.
Correspondence
Focke Ziemssen, University Eye Hospital
Tuebingen, Elfriede-Aulhorn-Str. 7, 72074 Tuebingen, Germany.
E: focke.ziemssen@med.uni-tuebingen.de
Support
The publication of this article was supported by Novartis.
Access
This article is published under the Creative Commons
Attribution Noncommercial License, which permits any non-commercial use,
distribution, adaptation and reproduction provided the original author(s) and
source are given appropriate credit.
Acknowledgements
The authors acknowledge Claire Bailey for her
significant contribution towards the design and conduct of the analysis and for
the development of this manuscript. Writing support was provided by Jennifer
Green (Green Ink Communications) and was funded by Novartis. William David
Strain would like to acknowledge the support of the National Institute for Health
Research (NIHR) Exeter Clinical Research Facility and the NIHR Biomedical
Research Centre scheme. The views expressed in this publication are those of
the author(s) and not necessarily those of the NIHR Exeter Clinical Research
Facility, the NHS, the NIHR or the Department of Health in England.
Received
2017-05-10T00:00:00
Further Resources
Trending Topic
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1 It has two forms: the first is a membrane-bound form, which is extensively expressed in the body, including the cells of the immune system, haematopoietic cells, […]
Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1 Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Gestational diabetes mellitus (GDM) is generally defined as “any degree of glucose tolerance with onset or first recognition during pregnancy”.1 It currently is one of the diseases with the highest morbidity among pregnant women.2 Determining its prevalence has been a ...
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are ...
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of ...
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this issue we feature a range of articles to keep you up to date with the latest discussions and developments in the field of medical endocrinology. We start with an ...
Type 1 diabetes mellitus (T1DM) is an autoimmune disease secondary to the destruction of the insulin-producing β cells of the islets of the pancreas. Environmental factors presumably trigger the disease in genetically susceptible individuals, leading to a lifetime dependency on exogenous ...
Highlights Enhanced external counterpulsation (EECP) is evaluated for glycaemic control in type 2 diabetes. Glycated haemoglobin reduction immediately after EECP therapy conclusion, after 2–4 weeks and after 7–12 weeks was -0.70%, 1.04% and 0.98%, respectively. EECP is associated with a significant lowering of blood pressure. ...
Diabetes mellitus (DM) is a group of metabolic disorders marked by elevated blood glucose. It has many subtypes, including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and neonatal diabetes; of these, T1DM and T2...
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1 For decades, glycated ...
Plan language summary Background The global COVID-19 pandemic resulted in an increased incidence of infection with Black fungus (Mucormycosis). However, the disease characteristics, chances of spread of infection and complications are not well known. Aim of the study We tried ...
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
